Mark Pirner, MD, PhD

Use of Supportive Medication for Opioid Withdrawal Syndrome in a Randomized, Placebo-Controlled Trial of Lofexidine

Introduction: Abrupt discontinuation of opioids after chronic use can result in severe, distressing symptoms that result from central noradrenergic hyperactivity. Avoidance of opioid with...

Mark Pirner , MD, PhD;

Thomas Clinch , MS;

11/22/2019

Consistent Efficacy of Lofexidine Across Primary and Secondary Efficacy Outcomes in a Large, Placebo-Controlled Trial

Introduction: Abrupt opioid withdrawal after chronic use results in central noradrenergic hyperactivity that is expressed clinically as opioid withdrawal syndrome (OWS). Patients with opi...

Mark Pirner , MD, PhD;

Thomas Clinch , MS;

11/22/2019